ClinicalTrials.gg
Not yet recruitingNCT06741202Updated Nov 9, 2026

Recovery-oriented Group Therapy for Veteran Men With Military Sexual Trauma

An interventional study of Men's MST Group and Present-Centered Group Therapy in Sexual Trauma, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

Updated Nov 9, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

VA has identified military sexual trauma (MST) as one of its highest priorities. MST is associated with increased prevalence of PTSD and depression, substance use disorders, suicide, difficulties maintaining relationships and employment, and homelessness. Yet important gender differences have been identified among MST survivors and many man may experience stigma and shame related to masculinity and sexuality. While gender-based shame appears central to MST-related distress and treatment underutilization, gender has often been overlooked in establishing evidence-based approaches, and no VA MST-related treatment has been developed specifically for men. To address this critical service gap, this study will collect data on improving treatment strategies and patient engagement for men with histories of MST. It will seek to develop strategies for enhancing a 12-session, gender-tailored group therapy for men MST survivors previously developed and implemented by the principal investigator. It will interview Veteran participants and mental health clinicians, conduct a pilot randomized trial, and evaluate feasibility within the VA, with the long-term goal of national implementation

Read the detailed description

Approximately 3.5% of Veteran men and 44% of Veteran women report a history of military sexual trauma (MST).Although women disproportionately experience MST, the absolute number of men who report MST (55,500 from 2004-2013) is relatively similar due to the larger proportion of men in the military. Further, MST likely remains vastly underreported among men, who experience multiple barriers to disclosure. Men survivors often wait decades to seek care for MST-related distress, contributing to pervasive life impairment.

MST is associated with transdiagnostic complexity and is associated with increased prevalence of PTSD and depression, substance use disorders, suicide, difficulties maintaining relationships and employment, and homelessness. Important gender differences have been identified among MST survivors: men may experience stigma and shame related to masculinity and sexuality; the probability of opioid use disorder among men with a history of MST is nearly double that of women; and men with histories of MST also experience more severe PTSD symptoms, chronic mental health symptoms, sexual dysfunction and distress, and greater risk for homelessness. While gender-based shame appears central to MST-related distress and treatment underutilization, gender has often been overlooked in establishing evidence-based approaches, and no VA MST-related treatment has been developed specifically for men.

To address this critical service gap, I designed a 12-session, gender-tailored, multi-modal, recovery-oriented group therapy for men MST survivors as part of my clinical responsibilities as a VA staff psychologist. My intervention (the Men's MST Group, or MMG), which I have been delivering continuously for 5 years, is based on the Integrated Recovery-oriented Model (IRM) for mental health services, and promotes agency through delivery of dynamic, exposure- and mindfulness-based techniques intended to improve distress management, social belongingness, and hope. This transdiagnostic intervention also seeks to reduce shame. Exploratory evaluation signaled strong retention, as well as recovery and attitudinal shifts, including reductions in shame and PTSD symptoms. As one participant noted after completing the MMG, "I can say the word 'rape' without shame." Given these initial findings, rigorous research is warranted to refine, test, and prepare for implementation of the intervention. Moreover, given the fact that most participants wait decades to seek treatment, more research is needed to facilitate men's utilization of MST-related services. In this proposed CDA, guided by Intervention Mapping and the Access Re-conceptualization Model, I plan to iteratively refine the MMG by interviewing Veteran participants and mental health clinicians, conducting a pilot randomized trial, and evaluating feasibility within the VA, with the long-term goal of national implementation.

This mentored CDA will fill gaps in my training - particularly in gender-tailored intervention development, intersectionality, clinical trials and health services research, and mixed methods - to support my independence as a VA clinician scientist focused on enhancing mental health services for vulnerable Veteran populations. The Specific Aims are to:

Aim 1. Revise the MMG treatment protocol, with attention to factors that will support men's access to, and engagement and retention in, mental health interventions. 1a) Conduct semi-structured qualitative interviews (n=24) with VA mental health clinicians, Vet Center clinicians, MST coordinators, and MST experts. Findings will inform protocol revisions. 1b) Review the revised protocol by conducting two focus groups with the two recent MMG cohorts (n=8). 1c) Convene an Expert Panel with selected Aim 1a participants and VA Operations Partners to finalize the protocol.

Aim 2. Using the revised protocol, conduct a pilot randomized controlled trial (RCT) with men MST survivors (n=32), randomized to the MMG or Present-Centered Group Therapy (PCGT; control condition) (four cohorts: 2 experimental, 2 control). Investigate engagement (session attendance) as well as recovery-oriented outcomes (agency, hope, belongingness, shame-reduction) and psychological symptoms (PTSD, MDD, suicidality) assessed at pre-, immediate post-, and 6-month post-intervention.

Aim 3. Assess pilot RCT findings and plan for multisite trial (Year 5 Merit). 3a) Conduct post-intervention semi-structured interviews with RCT participants and interventionists to understand treatment engagement factors as well as perceptions of accessibility, feasibility, acceptability, appropriateness, and effectiveness. 3b) Reconvene the Aim 1c Expert Panel to discuss RCT results and potential facilitators, barriers, and strategies for implementation of the MMG in usual VA mental health care. 3c) In collaboration with operations partners, enhance the protocol and design the intervention package with system-level considerations in preparation for a multisite trial.

VA has identified MST as one of its highest priorities. Given the prevalence of MST among men and the deleterious, often protracted MST-related symptomatology, it is critical to develop tailored services for this population. This application responds to VA HSR\&D's research priorities of suicide prevention, mental health, and health equity, and ORD's priorities of increasing the real-world impact of VA research and actively promoting equity.

02

Conditions studied

  • Sexual Trauma

Browse trials for

Keywords

  • military sexual trauma
  • veteran men
  • group therapy
03

In context

Sexual Trauma

14 studies on the registry are indexed under Sexual Trauma; 6 are open to participants now.

This study's planned enrollment of 32 is above the median of 26 across 12 interventional studies indexed under Sexual Trauma.

Browse Sexual Trauma studies →

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.

Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible participants include any individual who identifies as a Veteran cisgender man with a history of military sexual trauma (MST), English-speaking, and enrolled in the VA Greater Los Angeles (VAGLA). Participants must:

    • comprehend and sign the form
    • report a history of military sexual trauma (MST)
    • agree to complete research instruments
  • Because we are looking for a range of impact among men military sexual trauma (MST) survivors, participants will not be excluded based on psychiatric diagnosis

Exclusion criteria

Exclusion Criteria:

  • Per chart review conducted by the PI prior to screening and patient contact, Veterans will be excluded if they demonstrate:

    • severe suicidal or homicidal ideation, defined using the Columbia Suicide Severity Rating Scale (C-SSRS) and behavioral flags per chart review
    • severe and uncontrolled substance abuse (identified through current treatment of a substance use disorder in chart)
    • illness that inhibits engagement in study procedures (e.g., inability to attend in-person visits)
    • inability to self-consent to participate
    • completion of Cognitive Processing Therapy (CPT), Prolonged Exposure (PE) therapy, or the Men's MST Group (MMG) 5 or fewer years ago
    • concurrent enrollment in a trauma-focused intervention
  • Through chart review, Veterans who dropped out of these treatments after 3 sessions will still be eligible as this is considered "early dropout."
  • If immediate clinical attention is warranted, Veterans will receive immediate care via procedures outlined in the human subjects protection plan
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Men's MST Group (MMG)

    This is a 12-week long group that meets for 90 minutes weekly. This group will draw on interventions, developed in our pilot study, and also based on the PI's previous clinical experience designing and delivering a men's MST Group oriented to reduce psychiatric distress including identity-based shame by promoting group discussion among Veteran men about masculinity, sexuality, belongingness, and emotion regulation. The group is oriented around building core drivers of recovery: 1) agency through exposure- and mindfulness-based interventions to improve distress management; 2) social belongingness through group discussions on gender-specific themes; and 3) hope through coping skill training and treatment experienced as relevant. The protocol will be further revised based on research activity during Aims 1 and 2.

    Behavioral: Men's MST Group

  • Active comparator
    Present-Centered Group Therapy (PCGT)

    PCGT is a time-limited treatment for PTSD that focuses on increasing adaptive responses to current life stressors and difficulties that are directly or indirectly related to trauma or PTSD symptoms. PCGT was initially developed as a nonspecific comparison condition to test the effectiveness of trauma-focused cognitive behavioral therapy. The number of PCGT sessions has ranged from 12 to 32 for the group format, and is thus appropriate to utilize for the nature of this study. To minimize possible confounds, PCGT will be delivered for a 12-week period. The basis of PCGT is to provide "common factors" of psychotherapy, demonstrating the effects of what is unique in therapies. In this instance, PCGT may help articulate whether the effect of MMG is due to being gender-specific (bringing men together in the same group therapy setting) or being gender-tailored (delivering treatment that is specifically oriented to men, such as MMG group discussions).

    Behavioral: Present-Centered Group Therapy

Interventions

  • BehavioralMen's MST Group

    see above

  • BehavioralPresent-Centered Group Therapy

    see above

06

What researchers measure

Primary outcomes

  1. The Recovery Assessment Scale

    The Recovery Assessment Scale (RAS) is a 41-question forced choice 5-level Likert rating scale, designed to assess recovery, with emphasis on agency, hope, and belongingness, and shame-reduction-key constructs postulated to impact and be expressive of psychological distress and intra- and inter-personal avoidance.The RAS is the most widely used instrument to measure recovery and has good internal consistency, test-retest reliability, and interrater reliability. The scale ranges with a minimum score of 24 and a maximum score of 120; higher values signifying higher recovery.

    Time frame: up to 9 months

  2. External and Internal Shame Scale

    External and Internal Shame Scale (EISS) assesses global shame experience, with attention to its external and internal dimensions, relevant to men's MST. The scale consists of eight items, and measures four central shame domains: inferiority/inadequacy, sense of exclusion, uselessness/emptiness and criticism/judgment. This scale is found to have internal consistency and concurrent validity. The scale ranges with a minimum score of 0 and a maximum score of 32; higher values signifying higher levels of shame.

    Time frame: up to 9 months

  3. General Belongingness Scale

    General Belongingness Scale (GBS), a 12-item measure rated on a 7-point Likert scale, assesses a general sense of belonging, another indication of interpersonal distress pertaining to MST. This scale is a reliable and valid brief measure of general belongingness, and shows good cross-cultural validity. The scale ranges with a minimum score of 0 and a maximum score of 72; higher values signifying higher levels of belongingness.

    Time frame: up to 9 months

Secondary outcomes

  1. Post-Traumatic Checklist for The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (PCL-5)

    The PCL-5 is a 20-item non-MST specific self-report measure that assesses the DSM-5 symptoms of PTSD, a common indicator of MST-related distress. Each symptom is rated on a 5-point Likert scale assessing distress of each symptom. The PCL-5 has high reliability and validity, and provides a total and cluster symptom severity score corresponding with DSM-5 diagnostic criteria. The scale ranges with a minimum score of 0 and a maximum score of 80; higher values signifying higher levels of post-traumatic stress.

    Time frame: up to 9 months

  2. Patient Health Questionnaire-9

    Patient Health Questionnaire-9 (PHQ-9) is a widely used brief, 9-item instrument for screening, diagnosing, monitoring, and measuring the severity of depression over the course of two weeks. The PHQ-9 is a reliable and valid measure of depression severity that assess DSM criteria of depression, including suicidality. PHQ-9 has high cross-cultural validity and is often used in health care research. The scale ranges with a minimum score of 0 and a maximum score of 27; higher values signifying higher levels of depression.

    Time frame: up to 9 months

07

Study locations

1 site
08

References and documents

Publications

  • Yahalom J, Finley EP, O'Brien S, Yarns BC, Monteith LL, Lang AJ, Hamilton AB. Refining and Assessing Gender-Tailored Group Therapy for Veteran Men With Military Sexual Trauma: Protocol for a Mixed Methods Study. JMIR Res Protoc. 2026 Sep 1;15:e105373. doi: 10.2196/105373. PubMed 42679344 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 18, 2024
StartEst.
Nov 13, 2026was Oct 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 5, 2026→Nov 13, 2026
Nov 9, 2026
Eligibility
Minimum age none→18 Years; 3 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedEligible participants include any individual who identifies as a Veteran cisgender man with a history of military sexual trauma (MST), English-speaking, 18 years of age or older, and enrolled in the VA Greater Los Angeles (VAGLA). Participants must:
  • Editedreport a history of military sexual trauma (MST)
  • EditedBecause we are looking for a range of impact among men military sexual trauma (MST) survivors, participants will not be excluded based on psychiatric diagnosis
Exclusion criteria
  • Editedcompletion of Cognitive Processing Therapy (CPT), Prolonged Exposure (PE) therapy, or the Men's MST Group (MMG) 5 or fewer years ago
Nov 9, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42679344 ↗
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42679344 ↗
    Start date Oct 5, 2026→Nov 13, 2026
    Eligibility Minimum age none→18 Years; 3 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedEligible participants include any individual who identifies as a Veteran cisgender man with a history of military sexual trauma (MST), English-speaking, 18 years of age or older, and enrolled in the VA Greater Los Angeles (VAGLA). Participants must:
    • Editedreport a history of military sexual trauma (MST)
    • EditedBecause we are looking for a range of impact among men military sexual trauma (MST) survivors, participants will not be excluded based on psychiatric diagnosis
    Exclusion criteria
    • Editedcompletion of Cognitive Processing Therapy (CPT), Prolonged Exposure (PE) therapy, or the Men's MST Group (MMG) 5 or fewer years ago
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06741202
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Nov 13, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Jonathan Yahalom, PhD MA
Contact
jonathan.yahalom@va.gov
(310) 478-3711 ext. 43529
Alison B Hamilton, PhD MPH
Contact
Alison.Hamilton@va.gov
(310) 478-3711 ext. 44157
Jonathan Yahalom, PhD MA
principal investigator · VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion